Key Benefits
Why Families Turn to Jinshazhou
When Options Run Out
Jinshazhou Hospital of GZUCM isn't a last resort — it's where families come when they want precision, speed, and access to technologies that haven't reached the Philippines yet.
Western medicine attacks the tumour; TCM protects the patient. Herbal immunotherapy, acupuncture, and a structured 3-stage recovery protocol reduce chemo side effects, accelerate immune recovery, and create a body environment that resists recurrence — a dual-track approach unavailable in most Philippine oncology centres.
CyberKnife M6, NanoKnife, Proton Therapy, HIFU, Cryoablation, and more — all evaluated by a tumour board of ~10 doctoral-level specialists who deliver one unified written treatment plan within 72 hours. No fragmented second opinions. One team, one plan, one direction.
Treatments cost significantly less than comparable Western procedures, without compromising on technology or specialist expertise. Includes 500 VIP international wards, visa support, and a dedicated multilingual coordinator from day one.
Meet Your Hospital
Jinshazhou Hospital of GZUCM
Tour the facilities and see where your case will be reviewed and your treatment will take place.
The Technology Stack
Advanced Cancer Technologies
Jinshazhou Hospital of GZUCM provides access to advanced minimally invasive oncology tools — many of which are either unavailable in the Philippines or have waiting lists of months to years.
- →CyberKnife
- →Proton Therapy
- →Particle Knife
- →TomoTherapy H
- →TrueBeam
- →Halcyon
- →Ethos™ AI
- →Nanoknife (IRE)
- →CSA Cryotherapy
- →HIFU
- →Microwave & RFA
- →TACE / HAIC
- →Targeted Therapy & Immunotherapy
- →Yttrium-90 Microspheres
- →BNCT
- →Strontium-89 & Iodine-131
- →Phosphorus-32
- →Gamma Knife
- →Photon Knife
- →Varian HDR/LDR Brachytherapy
- →Da Vinci Robots
- →Ultrasound Focused Knife
- →Artificial Liver Support
- →Advanced Imaging (PET-MR, 4D CT)
- →Next-Generation Sequencing
- →Whole Exome Sequencing
Each technology includes clinical descriptions and real patient scenarios.
Collaborative Care
The MDT Model: One Patient, One Unified Plan
In the Philippines, most cancer patients move through the system alone — one referral at a time. You see a surgeon. The surgeon sends you to an oncologist. The oncologist refers you to a radiologist. Each doctor makes their call in isolation, without knowing what the others are thinking. Weeks pass. Decisions get made in silos.
At Jinshazhou Hospital of GZUCM, that doesn't happen. The moment your clinical dossier arrives, it is placed in front of a full Multidisciplinary Team — five specialists who each review your case independently, then sit together, challenge each other's assumptions, and reach consensus before anyone says a word to you.
What you receive at the end isn't five separate opinions you have to reconcile on your own. It's one document — a unified written treatment plan — that reflects the collective judgment of a surgeon, a radiation oncologist, a medical oncologist, a radiologist, and a TCM integrative specialist, all working from the same file, in the same room, on your case.
The specialists behind this process are not generalists filling a seat. Hospital-wide, Jinshazhou Hospital handles 1.2 million outpatients and 35,000 surgeries annually — a clinical volume that produces a depth of pattern recognition most hospitals never reach. Dr. Tan Yongcai alone has performed over 5,000 operations. The faculty includes nearly 10 dean-level experts and doctoral supervisors who have collectively published over 270 academic papers and hold 11 patents.
Several MDT leaders bring decades of international training. Dr. Wang Yang and Dr. Zhang Yanjun spent years in Australia and the United States specialising in advanced radiotherapy — and brought that expertise back to a hospital where it is applied daily, at scale, on cases like yours.
This matters more than it might sound. Many Filipino families arrive at Jinshazhou Hospital of GZUCM after months of back-and-forth between specialists at home — a surgeon who recommended waiting, an oncologist who suggested chemo first, a radiologist who wasn't sure. By the time they reach us, they are exhausted, confused, and no closer to a decision. The MDT process cuts through all of that. It replaces the noise with clarity.
The plan you receive is also not static. As your treatment progresses — after surgery, mid-chemotherapy, post-radiation — the MDT reconvenes. New imaging, new labs, new clinical data are fed back into the panel. The plan evolves with you, not ahead of you.
From the moment your dossier arrives to the moment the plan is in your hands — typically 72 hours. One process, one coordinated outcome.
What Happens When Your File Arrives
The moment your clinical dossier reaches GZUCM, it doesn't land on one doctor's desk — it lands on five.
Before anyone else says a word, the Diagnostic Radiologist pulls up your CT scans, PET images, and MRIs. They map the tumour in three dimensions — its size, its borders, which vessels it's touching, how close it sits to critical structures, whether lymph nodes are involved. They look for things a referring doctor may have missed. This radiological picture becomes the shared visual language for every specialist that follows. Without it, the rest of the panel is guessing.
Armed with that imaging, the Surgical Oncologist asks the hard question: can this be cut out — and should it be? They assess resection margins, vascular involvement, your performance status, and your fitness for anaesthesia. They consider whether surgery now would compromise later treatment options. Often, their answer shapes everything else — and sometimes, their answer is that surgery should wait, or not happen at all.
With the tumour mapped and surgical options on the table, the Radiation Oncologist determines whether CyberKnife, Proton Therapy, TomoTherapy, or 125I seed implantation can do what surgery cannot — reaching the tumour with sub-millimetre precision while sparing healthy tissue entirely. They calculate dosing, fractionation, and sequencing relative to any planned chemotherapy, so the two don't work against each other.
Your pathology report and molecular biomarker panel tell this specialist what your tumour is made of — and what it will respond to. EGFR mutation? HER2 amplification? PD-L1 expression? MSI-high status? They match your tumour's molecular fingerprint to the most effective targeted agent or immunotherapy regimen available. Many of these drugs are approved and accessible in China months or years before they reach the Philippines or other ASEAN markets.
While the others plan how to attack the tumour, the Traditional Chinese Medicine specialist plans how to protect you. They design a complementary protocol — herbal supportive formulas, acupuncture to help manage pain and nausea, and a structured 3-stage recovery plan covering the first month post-surgery, the adjuvant therapy window, and long-term consolidation. The goal is not just survival. It is to keep your body as strong as possible throughout treatment and beyond.
Then they sit in the same room.
Every specialist presents their independent findings. Disagreements surface. Assumptions get challenged. A surgeon might recommend resection; the radiation oncologist might argue CyberKnife achieves the same outcome with a shorter recovery. The medical oncologist might flag a biomarker that changes the sequencing entirely. This tension is the point — because the plan that emerges from it is stronger than any single specialist could have produced alone. In most cases within 72 hours, that plan is written, signed, and in your hands.
Why Timing Matters
Detection & Treatment Timing — Outcome Matrix
Four possible journeys for a cancer patient. Detection timing and treatment timing are independent decisions — and each combination produces a measurably different outcome.
Earlier detection and earlier treatment are both independently associated with better outcomes and lower overall cost in oncology generally — this is not a claim about outcomes specific to Jinshazhou Hospital of GZUCM, and not a guarantee of any result. Individual outcomes vary by cancer type, stage, overall health, and treatment response. Consult our MDT team for a personalized evaluation of your case.
Detection
Cancer caught before it spreads. Typically one treatment course, shorter duration.
Detected early but treatment was delayed. More complex treatment may be required than if started promptly.
Detection
Found at an advanced stage but treatment started immediately. Higher cost, longer treatment course.
Cancer found late and treatment further delayed. Highest cost, most complex treatment course.
Patients treated at Stage I or II typically complete treatment in months rather than years, with a comparatively simpler course of care.
Modern treatment options continue to advance care for later-stage cases. An MDT review can clarify what's realistically achievable for a specific case.
Submit a case for MDT review to get a clear picture of the treatment options available.
Get Your Case Reviewed →
A Personal Note
Why MediDocPH Exists
MediDocPH was founded after Kel coordinated treatment for his late wife, Tel, at Jinshazhou Hospital of GZUCM, including Local Targeted Chemotherapy — one of the precision treatments featured on this page. That experience shaped how this platform is built to support Filipino families navigating treatment abroad.
Read Tel's Full Story →Ready to See Your Options?
Typically within 72 hours, five specialists can review your case and deliver a unified treatment plan — free to begin.
Speak with a CoordinatorFree to start · No commitment · Response within 24 hours